CYCN
Cyclerion Therapeutics, Inc.1.5300
-0.0700-4.38%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
5.82MP/E (TTM)
-Basic EPS (TTM)
-0.70Dividend Yield
0%Recent Filings
8-K
FDA nods CYC-126 Phase 2
Cyclerion Therapeutics received positive FDA pre-IND feedback on February 17, 2026, supporting CYC-126's Phase 2 proof-of-concept study design for treatment-resistant depression. The company formed a clinical advisory board with five experts in neuropsychiatry and anesthesiology. Phase 2 initiation stays on track for H2 2026. FDA guidance bolsters regulatory path.
8-K
Medsteer collab accelerates CYC-126
Cyclerion Therapeutics inked a collaboration with Medsteer on January 3, 2026, securing a royalty-free license to Medsteer's closed-loop anesthetic tech and an exclusive option for broader rights outside surgery/ICU uses. Up to $3.7M in milestones plus low single-digit royalties await. This bolsters CYC-126's Phase 2 POC launch in H2 2026. Going concern doubts linger.
8-K
Akebia triggers $1M milestone
10-Q
Q3 FY2025 results
Cyclerion posted Q3 revenue of $875K, up sharply from $194K y/y, fueled by an $800K Akebia purchase agreement and $75K from a now-terminated olinciguat option, yet posted a $1.0M operating loss, narrower than last year's $1.1M (derived). YTD revenue hit $1.0M versus $194K y/y, with net loss shrinking to $2.7M from $3.6M, thanks to a $1.3M insurance recovery; cash burn slowed to $1.7M from $4.7M, offset by $3.1M from equity raises, leaving $4.6M in cash. Signed MIT license in September 2025 for TRD therapy tech. Cash lasts into Q2 2026. Going concern doubt lingers.
8-K
MIT license for depression tech
Cyclerion Therapeutics inked an exclusive worldwide license with MIT on September 19, 2025, for patent rights targeting neuropsychiatric disorders like treatment-resistant depression. Terms include a nominal upfront, up to $4.4 million in milestones, and low single-digit royalties. The deal anchors a relaunch into neuropsychiatry, with Phase 2 trial eyed for 2026. Funding remains a going concern risk.
BCYC
Bicycle Therapeutics plc
7.31-0.02
CGTX
Cognition Therapeutics, Inc.
1.52-0.08
CLRB
Cellectar Biosciences, Inc.
3.18-0.02
CVKD
Cadrenal Therapeutics, Inc.
8.25-4.04
CYBN
Cybin Inc.
6.66+0.00
CYTK
Cytokinetics, Incorporated
62.02-0.14
ENVB
Enveric Biosciences, Inc.
5.24-0.12
LIANY
LianBio
0.09+0.00
SION
Sionna Therapeutics, Inc.
42.89+0.13
UNCY
Unicycive Therapeutics, Inc.
5.88+0.00